Mabion SA 2017 AR2
The report outlines Mabion S.A.'s operations, financial position, and development strategy for the fiscal year 2017. Key highlights include receiving a GMP certificate for the Scientific-Industrial Complex in Konstantynów Łódzki and obtaining positive clinical trial results for MabionCD20 in patients with rheumatoid arthritis and non-Hodgkin's lymphomas. The company also secured significant co-financing from the National Centre for Research and Development (NCBiR) for its R&D projects. Additionally, Mabion S.A. expanded its intellectual property by filing a European patent application for an innovative multiple sclerosis therapy, MabionMS.
Company: Mabion SA
Sector: Manufacturing
Country: Poland
Year: 2017
Type: AR2
Pages: 79
Back to company
Mabion SA
Directors' Report
The report outlines Mabion S.A.'s operations, financial position, and development strategy for the fiscal year 2017. Key highlights include receiving a GMP certificate for the Scientific-Industrial Complex in Konstantynów Łódzki and obtaining positive clinical trial results for MabionCD20 in patients with rheumatoid arthritis and non-Hodgkin's lymphomas. The company also secured significant co-financing from the National Centre for Research and Development (NCBiR) for its R&D projects. Additionally, Mabion S.A. expanded its intellectual property by filing a European patent application for an innovative multiple sclerosis therapy, MabionMS.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2017
Reporting Period
Jan 1, 2017 - Dec 31, 2017
Fiscal Year
2017
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees